Recherche

Afficher tous les résultats pour

Accueil

Personne

Patrick Aebischer

À propos
Confidentialité
Mentions légales

Graph Chatbot

Publications associées (172)

Page 5 sur 9

Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6

Patrick Aebischer, Bernard Schneider, Christopher Towne

Retrograde transport of viral vectors in the rodent spinal cord provides a powerful means to administer a therapeutic transgene from the innervated musculature. With the aim of scaling up this approach to non-human primates, we have injected recombinant ad ...

2010

In vivo calcium deposition on polyvinyl alcohol matrix used in hollow fiber cell macroencapsulation devices

Patrick Aebischer, Nicolas Bouche

The encapsulation of genetically modified cells represents a promising approach for the delivery of therapeutic proteins. The functionality of the device is dependent on the characteristics of the biomaterials, the procedures used in its confection and the ...

2004

Efficient gene transfer and expression of biologically active glial cell line-derived neurotrophic factor in rat motoneurons transduced wit lentiviral vectors

Patrick Aebischer, Nicole Déglon

Several studies have shown the ability of human immunodeficiency virus type 1 (HIV1)-based lentiviral vectors to infect nondividing brain and retinal neurons with high efficiency and long-term expression of the transduced gene. We show that purified embryo ...

Wiley-Blackwell2000

Viral vectors as a tool to model and treat Parkinson's disease

Patrick Aebischer, Jean-Charles Bensadoun

2006

Channel-Mediated Lactate Release by K+-Stimulated Astrocytes

Pierre Magistretti, Patrick Aebischer, Bernard Schneider, Sylvain Eric Lengacher

Excitatory synaptic transmission is accompanied by a local surge in interstitial lactate that occurs despite adequate oxygen availability, a puzzling phenomenon termed aerobic glycolysis. In addition to its role as an energy substrate, recent studies have ...

Society for Neuroscience2015

Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity

Patrick Aebischer, Marco Cantoni, Graham Knott, Ralf Schneggenburger, Jean-Charles Bensadoun, Wojciech Janusz Bobela, Özgür Genç

alpha-Synuclein (alpha-syn) is a presynaptic protein present at most nerve terminals, but its function remains largely unknown. The familial forms of Parkinson's disease associated with multiplications of the alpha-syn gene locus indicate that overabundanc ...

Springer-Verlag2012

A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension

Patrick Aebischer, Nicole Déglon

Current therapy for several forms of anemia involves a weekly regime of multiple subcutaneous injections of recombinant human erythropoietin (hEpo). In an effort to provide a physiologically regulated administration of erythropoietin, we are developing cel ...

1997

Alpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease

Patrick Aebischer, Bernard Schneider, Wojciech Janusz Bobela

Accumulation and misfolding of the alpha-synuclein protein are core mechanisms in the pathogenesis of Parkinson's disease. While the normal function of alpha-synuclein is mainly related to the control of vesicular neurotransmission, its pathogenic effects ...

Mdpi Ag2015

In vivo performance of a new biodegradable polyester urethane system used as a nerve guidance channel

Patrick Aebischer

Biodegradable nerve guidance channels (NGCs) represent a promising alternative to current clinical nerve repair procedures. To be suitable as a NGC material, the polymer system should possess elastomeric properties and degrade at a defined rate without int ...

1998

Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease

Patrick Aebischer, Bernard Schneider, Christophe Lo Bianco

Parkinson's disease (PD) is characterized by a progressive loss of midbrain dopamine neurons and the presence of cytoplasmic inclusions called Lewy bodies. Mutations in several genes including alpha-synuclein and parkin have been linked to familial PD. The ...

National Academy of Sciences2004

Synergistic Effects of GDNF and VEGF on Lifespan and Disease Progression in a Familial ALS Rat Model

Patrick Aebischer

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of motor neurons in the brain and spinal cord. We have recently shown that human mesenchymal stem cells (hMSCs) modified to release glial cell li ...

Nature Publishing Group2013

Wlds-mediated protection of dopaminergic fibers in an animal model of Parkinson disease

Patrick Aebischer, Bernard Schneider

Parkinson disease (PD) is characterized by the progressive degeneration of substantia nigra dopaminergic neurons projecting to the striatum. Since the deficit in striatal dopamine is the main cause of PD symptoms, it appears critical to preserve axon termi ...

2004

A high-capacity cell macroencapsulation system supporting the long-term survival of genetically engineered allogeneic cells

Matthias Lütolf, Patrick Aebischer, Bernard Schneider, Steffen Cosson, Aurélien Lathuilière

The rapid increase in the number of approved therapeutic proteins, including recombinant antibodies, for diseases necessitating chronic treatments raises the question of the overall costs imposed on healthcare systems. It is therefore important to investig ...

Elsevier2014

Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF

Patrick Aebischer, Frédéric Kaplan, Nicole Déglon

The gene therapy approach presented in this protocol employs a polymer encapsulated, xenogenic, transfected cell line to release human ciliary neurotrophic factor (hCNTF) for the treatment of Amyotrophic Lateral Sclerosis (ALS). A tethered device, containi ...

1996

Central nervous system delivery of recombinant ciliary neurotrophic factor by polymer encapsulated differentiated C2C12 myoblasts

Patrick Aebischer, Nicole Déglon

Neurotrophic factors hold promise for the treatment of neurodegenerative diseases. Intrathecal transplantation of polymer encapsulated cell lines genetically engineered to release neurotrophic factors provides a means to deliver them continuously behind th ...

1996

Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults A Randomized Clinical Trial

Patrick Aebischer

IMPORTANCE Aging is associated with a decline in mitochondrial function and reduced exercise capacity. Urolithin A is a natural gut microbiome-derived food metabolite that has been shown to stimulate mitophagy and improve muscle function in older animals a ...

AMER MEDICAL ASSOC2022

Allogeneic beta-islet cells correct diabetes and resist immune rejection

Patrick Aebischer

Allogeneic MHC-incompatible organ or cell grafts are usually promptly rejected by immunocompetent hosts. Here we tested allogeneic beta-islet cell graft acceptance by immune or naive C57BL/6 mice rendered diabetic with streptozotocin (STZ). Fully MHC-misma ...

National Academy of Sciences2002

Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults

Johan Auwerx, Patrick Aebischer, Pénélope Andreux

Targeting mitophagy to activate the recycling of faulty mitochondria during aging is a strategy to mitigate muscle decline. We present results from a randomized, placebo-controlled trial in middle-aged adults where we administer a postbiotic compound Uroli ...

2022

Treatment of amyotrophic lateral sclerosis using a gene therapy approach

Patrick Aebischer

Neurotrophic factors which act on motor neurons may provide an efficient treatment for amyotrophic lateral sclerosis. In order to overcome the difficulty of administering proteins into the central nervous system, it is possible to use a gene therapy approa ...

1995

Development Of A Cell Encapsulation Approach For Human Anti-Tumor Immunotherapy

Patrick Aebischer

2008